These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38512021)

  • 41. Application of Small Cell Lung Cancer Molecular Subtyping Markers to Small Cell Neuroendocrine Carcinoma of the Cervix: NEUROD1 as a Poor Prognostic Factor.
    Kim G; Kim M; Nam EJ; Lee JY; Park E
    Am J Surg Pathol; 2024 Mar; 48(3):364-372. PubMed ID: 37981832
    [TBL] [Abstract][Full Text] [Related]  

  • 42. miR-375 is highly expressed and possibly transactivated by achaete-scute complex homolog 1 in small-cell lung cancer cells.
    Zhao H; Zhu L; Jin Y; Ji H; Yan X; Zhu X
    Acta Biochim Biophys Sin (Shanghai); 2012 Feb; 44(2):177-82. PubMed ID: 22172490
    [TBL] [Abstract][Full Text] [Related]  

  • 43. NEUROD1 is highly expressed in extensive-disease small cell lung cancer and promotes tumor cell migration.
    Ikematsu Y; Tanaka K; Toyokawa G; Ijichi K; Ando N; Yoneshima Y; Iwama E; Inoue H; Tagawa T; Nakanishi Y; Okamoto I
    Lung Cancer; 2020 Aug; 146():97-104. PubMed ID: 32526603
    [TBL] [Abstract][Full Text] [Related]  

  • 44. BET Inhibitors Target the SCLC-N Subtype of Small-Cell Lung Cancer by Blocking NEUROD1 Transactivation.
    Chen H; Gesumaria L; Park YK; Oliver TG; Singer DS; Ge K; Schrump DS
    Mol Cancer Res; 2023 Feb; 21(2):91-101. PubMed ID: 36378541
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Unravelling the biology of SCLC: implications for therapy.
    Sabari JK; Lok BH; Laird JH; Poirier JT; Rudin CM
    Nat Rev Clin Oncol; 2017 Sep; 14(9):549-561. PubMed ID: 28534531
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Induced degradation of lineage-specific oncoproteins drives the therapeutic vulnerability of small cell lung cancer to PARP inhibitors.
    Kim C; Wang XD; Liu Z; Hao J; Wang S; Li P; Zi Z; Ding Q; Jang S; Kim J; Luo Y; Huffman KE; Pal Choudhuri S; Del Rio S; Cai L; Liang H; Drapkin BJ; Minna JD; Yu Y
    Sci Adv; 2024 Jan; 10(3):eadh2579. PubMed ID: 38241363
    [TBL] [Abstract][Full Text] [Related]  

  • 47. NDR1 activates CD47 transcription by increasing protein stability and nuclear location of ASCL1 to enhance cancer stem cell properties and evasion of phagocytosis in small cell lung cancer.
    Wang LL; Wan XY; Wang TL; Liu CQ; Zheng FM
    Med Oncol; 2022 Oct; 39(12):254. PubMed ID: 36224405
    [TBL] [Abstract][Full Text] [Related]  

  • 48. SMARCA4 controls state plasticity in small cell lung cancer through regulation of neuroendocrine transcription factors and REST splicing.
    Redin E; Sridhar H; Zhan YA; Pereira Mello B; Zhong H; Durani V; Sabet A; Manoj P; Linkov I; Qiu J; Koche RP; de Stanchina E; Astorkia M; Betel D; Quintanal-Villalonga Á; Rudin CM
    J Hematol Oncol; 2024 Jul; 17(1):58. PubMed ID: 39080761
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification of deregulation of apoptosis and cell cycle in neuroendocrine tumors of the lung via NanoString nCounter expression analysis.
    Walter RF; Werner R; Ting S; Vollbrecht C; Theegarten D; Christoph DC; Schmid KW; Wohlschlaeger J; Mairinger FD
    Oncotarget; 2015 Sep; 6(28):24690-8. PubMed ID: 26008974
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition of p62/SQSTM1 sensitizes small-cell lung cancer cells to cisplatin-induced cytotoxicity by targeting NEDD9 expression.
    Xu L; Xu F; Kong Q; Yang T; Tan D; Zhang X; Li N; Zhao S; Zhao J; Li M
    Mol Carcinog; 2020 Aug; 59(8):967-979. PubMed ID: 32424979
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The prognostic implications of Notch1, Hes1, Ascl1, and DLL3 protein expression in SCLC patients receiving platinum-based chemotherapy.
    Tendler S; Kanter L; Lewensohn R; Ortiz-Villalón C; Viktorsson K; De Petris L
    PLoS One; 2020; 15(10):e0240973. PubMed ID: 33104707
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High mRNA expression of POU2F3 in small cell lung cancer cell lines predicts the effect of lurbinectedin.
    Matsui S; Haruki T; Oshima Y; Kidokoro Y; Sakabe T; Umekita Y; Nakamura H
    Thorac Cancer; 2022 Apr; 13(8):1184-1192. PubMed ID: 35278040
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Transformation to small cell lung cancer is irrespective of EGFR and accelerated by SMAD4-mediated ASCL1 transcription independently of RB1 in non-small cell lung cancer.
    Ding X; Shi MX; Liu D; Cao JX; Zhang KX; Zhang RD; Zhang LP; Ai KX; Su B; Zhang J
    Cell Commun Signal; 2024 Jan; 22(1):45. PubMed ID: 38233864
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Distinct microRNA Signature and Suppression of ZFP36L1 Define ASCL1-Positive Lung Adenocarcinoma.
    Enokido T; Horie M; Yoshino S; Suzuki HI; Matsuki R; Brunnström H; Micke P; Nagase T; Saito A; Miyashita N
    Mol Cancer Res; 2024 Jan; 22(1):29-40. PubMed ID: 37801008
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Molecular Subtypes of Primary SCLC Tumors and Their Associations With Neuroendocrine and Therapeutic Markers.
    Qu S; Fetsch P; Thomas A; Pommier Y; Schrump DS; Miettinen MM; Chen H
    J Thorac Oncol; 2022 Jan; 17(1):141-153. PubMed ID: 34534680
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of ASCL1, NEUROD1, and POU2F3 expression in surgically resected specimens, paired tissue microarrays, and lymph node metastases in small cell lung carcinoma.
    Handa T; Hayashi T; Ura A; Watanabe I; Takamochi K; Onagi H; Kishi M; Matsumoto N; Tajima K; Kishikawa S; Saito T; Takahashi K; Suzuki K; Yao T
    Histopathology; 2023 May; 82(6):860-869. PubMed ID: 36715573
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chemotherapy-Regulated microRNA-125-HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer.
    Yagishita S; Fujita Y; Kitazono S; Ko R; Nakadate Y; Sawada T; Kitamura Y; Shimoyama T; Maeda Y; Takahashi F; Takahashi K; Tamura T; Koizumi F
    Mol Cancer Ther; 2015 Jun; 14(6):1414-23. PubMed ID: 25833836
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway.
    Liu H; Huang J; Peng J; Wu X; Zhang Y; Zhu W; Guo L
    Mol Cancer; 2015 Mar; 14():59. PubMed ID: 25880778
    [TBL] [Abstract][Full Text] [Related]  

  • 59. EGFR mediates activation of RET in lung adenocarcinoma with neuroendocrine differentiation characterized by ASCL1 expression.
    Bhinge K; Yang L; Terra S; Nasir A; Muppa P; Aubry MC; Yi J; Janaki N; Kovtun IV; Murphy SJ; Halling G; Rahi H; Mansfield A; de Andrade M; Yang P; Vasmatzis G; Peikert T; Kosari F
    Oncotarget; 2017 Apr; 8(16):27155-27165. PubMed ID: 28460442
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Epithelial Sodium Channel (αENaC) Is a Downstream Therapeutic Target of ASCL1 in Pulmonary Neuroendocrine Tumors.
    He M; Liu S; Gallolu Kankanamalage S; Borromeo MD; Girard L; Gazdar AF; Minna JD; Johnson JE; Cobb MH
    Transl Oncol; 2018 Apr; 11(2):292-299. PubMed ID: 29413762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.